...
首页> 外文期刊>BMC Musculoskeletal Disorders >Association of cardiotrophin-like cytokine factor 1 levels in peripheral blood mononuclear cells with bone mineral density and osteoporosis in postmenopausal women
【24h】

Association of cardiotrophin-like cytokine factor 1 levels in peripheral blood mononuclear cells with bone mineral density and osteoporosis in postmenopausal women

机译:白细胞状细胞因子1水平在绝经后妇女骨密度和骨质疏松骨质细胞外周血单核细胞中

获取原文
           

摘要

Recent research has suggested that cardiotrophin-like cytokine factor 1 (CLCF1) may be an important regulator of bone homeostasis. Furthermore, a whole gene chip analysis suggested that the expression levels of CLCF1 in the peripheral blood mononuclear cells (PBMCs) were downregulated in postmenopausal women with osteoporosis. This study aimed to assess whether the expression levels of CLCF1 in PBMCs can reflect the severity of bone mass loss and the related fracture risk. In all, 360 postmenopausal women, aged 50 to 80?years, were included in the study. A survey to evaluate the participants’ health status, measurement of bone mineral density (BMD), routine blood test, and CLCF1 expression level test were performed. Based on the participants’ bone health, 27 (7.5%), 165 (45.83%), and 168 (46.67%) participants were divided into the normal, osteopenia, and osteoporosis groups, respectively. CLCF1 protein levels in the normal and osteopenia groups were higher than those in the osteoporosis group. While the CLCF1 mRNA level was positively associated with the BMD of total femur (r = 0.169, p = 0.011) and lumbar spine (r = 0.176, p = 0.001), the protein level was positively associated with the BMD of the lumbar spine (r = 0.261, p ?0.001), femoral neck (r = 0.236, p = 0.001), greater trochanter (r = 0.228, p = 0.001), and Ward’s triangle (r = 0.149, p = 0.036). Both the mRNA and protein levels were negatively associated with osteoporosis development (r = ??0.085, p = 0.011 and r = ??0.173, p = 0.014, respectively). The association between CLCF1 protein level and fracture risk was not significant after adjusting for BMD. To our knowledge, this is the first clinical study to show that CLCF1 expression levels in the PBMCs of postmenopausal women can reflect the amount of bone mass or the severity of bone mass loss.
机译:最近的研究表明,白细胞状细胞因子因子1(CLCF1)可能是骨稳态的重要调节因子。此外,全基因芯片分析表明,外周血单核细胞(PBMC)中CLCF1的表达水平在患有骨质疏松症的绝经后妇女中下调。本研究旨在评估PBMC中CLCF1的表达水平是否可以反映骨质损失的严重程度和相关的骨折风险。总之,360名绝经后妇女,年龄在50至80岁以下的妇女,年龄在研究中被纳入。评估参与者的健康状况,骨矿物密度(BMD)测量,常规血液试验和CLCF1表达水平试验进行调查。基于参与者的骨骼健康,分别分别分别分为27(7.5%),165(45.83%)和168名(46.67%)分别分为正常,骨质增多和骨质疏松症组。 CLCF1正常和骨内血群中的蛋白质水平高于骨质疏松症组中的蛋白质水平。虽然CLCF1 mRNA水平与总股骨的BMD呈正相关(r = 0.169,p = 0.011)和腰椎(r = 0.176,p = 0.001),但蛋白质水平与腰椎的BMD呈正相关( r = 0.261,p& 0.001),股骨颈(r = 0.236,p = 0.001),更大的脱胶(r = 0.228,p = 0.001)和病房的三角形(r = 0.149,p = 0.036)。 mRNA和蛋白质水平分别与骨质疏松症发育(R = 0.085,P = 0.011和R = 0.173,P = 0.014分别是负相关的。 CLCF1蛋白质水平与骨折风险之间的关联在调整BMD后不显着。据我们所知,这是第一次临床研究表明,绝经后妇女PBMC中的CLCF1表达水平可以反映骨量或骨量损失的严重程度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号